Insights

Innovative Platform EyeGate Pharmaceuticals utilizes proprietary hyaluronic acid-based gel technology and iontophoresis delivery systems, offering unique treatment solutions that can be extended to other ocular indications or drug formulations seeking effective delivery mechanisms and tissue healing.

Clinical Development Focus The company’s active pipeline includes products targeting eye inflammation, pain management, and corneal healing, presenting opportunities to collaborate or supply complementary therapeutics and expand into related ophthalmic areas.

Strategic Partnerships EyeGate’s licensing agreements with Valeant for the treatment of uveitis and post-surgical inflammation signify openness to commercial partnerships, indicating potential for distribution, co-marketing, or licensing agreements to extend product reach.

Funding and Growth With recent funding and a focus on clinical-stage products, there is potential to provide early-stage clinical supplies, specialized equipment, or expand sales efforts into hospital and surgical centers involved in ophthalmic treatments.

Market Expansion The company's innovative treatments for ocular surface disorders and post-operative care align well with expanding ophthalmology markets, especially in surgical and treatment centers seeking advanced therapeutics for eye disease management.

Similar companies to EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals, Inc. Tech Stack

EyeGate Pharmaceuticals, Inc. uses 8 technology products and services including Open Graph, Webpack, Module Federation, and more. Explore EyeGate Pharmaceuticals, Inc.'s tech stack below.

  • Open Graph
    Content Management System
  • Webpack
    Development
  • Module Federation
    Development
  • Google Fonts API
    Font Scripts
  • Font Awesome
    Font Scripts
  • JSON-LD
    Javascript Frameworks
  • Nginx
    Web Servers
  • Apache HTTP Server
    Web Servers

Media & News

EyeGate Pharmaceuticals, Inc.'s Email Address Formats

EyeGate Pharmaceuticals, Inc. uses at least 1 format(s):
EyeGate Pharmaceuticals, Inc. Email FormatsExamplePercentage
FLast@eyegatepharma.comJDoe@eyegatepharma.com
39%
First.Last@eyegatepharma.comJohn.Doe@eyegatepharma.com
11%
FLast@eyegatepharma.comJDoe@eyegatepharma.com
39%
First.Last@eyegatepharma.comJohn.Doe@eyegatepharma.com
11%

Frequently Asked Questions

What is EyeGate Pharmaceuticals, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact EyeGate Pharmaceuticals, Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is EyeGate Pharmaceuticals, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
EyeGate Pharmaceuticals, Inc.'s official website is eyegatepharma.com and has social profiles on LinkedIn.

How much revenue does EyeGate Pharmaceuticals, Inc. generate?

Minus sign iconPlus sign icon
As of December 2025, EyeGate Pharmaceuticals, Inc.'s annual revenue is estimated to be $2M.

What is EyeGate Pharmaceuticals, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
EyeGate Pharmaceuticals, Inc.'s SIC code is 2835 - In Vitro and In Vivo Diagnostic Substances NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does EyeGate Pharmaceuticals, Inc. have currently?

Minus sign iconPlus sign icon
As of December 2025, EyeGate Pharmaceuticals, Inc. has approximately 17 employees across 2 continents, including North AmericaAsia. Key team members include President, Chief Executive Officer And A Director: P. A.Senior Quality Assurance Manager: K. S.Principal: C. G.. Explore EyeGate Pharmaceuticals, Inc.'s employee directory with LeadIQ.

What industry does EyeGate Pharmaceuticals, Inc. belong to?

Minus sign iconPlus sign icon
EyeGate Pharmaceuticals, Inc. operates in the Pharmaceutical Manufacturing industry.

What technology does EyeGate Pharmaceuticals, Inc. use?

Minus sign iconPlus sign icon
EyeGate Pharmaceuticals, Inc.'s tech stack includes Open GraphWebpackModule FederationGoogle Fonts APIFont AwesomeJSON-LDNginxApache HTTP Server.

What is EyeGate Pharmaceuticals, Inc.'s email format?

Minus sign iconPlus sign icon
EyeGate Pharmaceuticals, Inc.'s email format typically follows the pattern of FLast@eyegatepharma.com. Find more EyeGate Pharmaceuticals, Inc. email formats with LeadIQ.

How much funding has EyeGate Pharmaceuticals, Inc. raised to date?

Minus sign iconPlus sign icon
As of December 2025, EyeGate Pharmaceuticals, Inc. has raised $11M in funding. The last funding round occurred on Aug 10, 2021 for $11M.

EyeGate Pharmaceuticals, Inc.

Pharmaceutical ManufacturingMassachusetts, United States11-50 Employees

Traded on Nasdaq Capital Market, stock symbol EYEG, EyeGate is a clinical-stage specialty pharmaceutical company that develops and commercializes products using two proprietary platform technologies for treating diseases and disorders of the eye.

Our most advanced platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form of the natural polymer hyaluronic acid (“HA”), which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface.

Our first CMHA-S-based product candidate, the EyeGate Ocular Bandage Gel (“OBG”), is a topically applied eye drop formulation that has completed its first-in-man clinical trial for the healing and lubricating of large epithelial defects following treatment after photorefractive keratectomy (“PRK”) surgery.

Our initial product candidate from our second platform is EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues through our proprietary innovative iontophoresis drug delivery system, the EyeGate® II Delivery System. 

More than 2,400 treatments have been administered to date using our EyeGate® II Delivery System in clinical trials. EGP-437 is currently in clinical development for the treatment of various inflammatory conditions of the eye, including ocular inflammation and pain in post-surgical cataract patients and the treatment of uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. 

EyeGate has entered into two exclusive, worldwide licensing agreements with subsidiaries of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) through which we have granted Valeant an exclusive, worldwide commercial and manufacturing rights to the EGP-437 combination product for the treatment of uveitis and post-operative ocular inflammation and pain in ocular surgery patients.

Section iconCompany Overview

Phone number
SIC Code
2835 - In Vitro and In Vivo Diagnostic Substances
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Employees
11-50

Section iconFunding & Financials

  • $11M

    EyeGate Pharmaceuticals, Inc. has raised a total of $11M of funding over 13 rounds. Their latest funding round was raised on Aug 10, 2021 in the amount of $11M.

  • $1M

    EyeGate Pharmaceuticals, Inc.'s revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $11M

    EyeGate Pharmaceuticals, Inc. has raised a total of $11M of funding over 13 rounds. Their latest funding round was raised on Aug 10, 2021 in the amount of $11M.

  • $1M

    EyeGate Pharmaceuticals, Inc.'s revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.